ClinicalTrials.gg
CompletedNCT03748134Updated Oct 24, 2023

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

A Phase 3 interventional study of Sintilimab and Cisplatin in Esophageal Squamous Cell Carcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 48 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
746
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma — 9 open to participants now, 9 under way, 4 of them phase 3. sintilimab · Esophageal Squamous Cell Carcinoma.

Enrollment
Largest of 21
746 · median 52
Started
2018
the only one that year
Phase 3
5 of 21
4 open now
Registered
2nd of 21
by date
Lead sponsor
2 of 21
Innovent Biologics (Suzhou) Co. Ltd.

Among the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, this one has the largest enrollment, is the only one that started in 2018, is one of 5 in phase 3, and was the 2nd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

9 of the 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sintilimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.

After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma

Keywords

  • ESCC
  • Esophageal Cancer
  • Esophageal Neoplasms
  • Esophageal Neoplasms Malignant
  • Esophageal Squamous Cell Carcinoma
  • Neoplasms, Squamous Cell
  • Esophageal Diseases
  • Carcinoma, Squamous Cell
  • Gastrointestinal Diseases
  • Paclitaxel
  • Cisplatin
  • Fluorouracil
  • Antineoplastic Agents
  • Anti-PD-1
  • Sintilimab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Histopathologically confirmed unresectable, locally advanced, recurrent or ESCC (excluding mixed adenosquamous carcinoma and other histological subtypes)
  • PS of 0 or 1
  • Subject must be unsuitable for definitive treatment, such as definitive chemoradiotherapy and/or surgery. For subjects who have received (neo) or definitive chemotherapy/radiochemotherapy, time from the completion of last treatment to disease recurrence must be > 6 months Could provide archival or fresh tissues for expression analysis with obtainable results
  • Have at least one as per v1.1

Key exclusion Criteria:

  • ESCC with endoscopy-confirmed near-complete obstruction requiring interventional therapy
  • Post stent implantation in the esophagus or trachea with risk of perforation
  • Received systemic treatment for advanced or metastatic ESCC.
  • Received a cumulative dose of cisplatin ≥ 300 mg/m2 and the last cisplatin dose was within 12 months of randomization or the first dose of study treatment in the open-label phase.
  • High risk of hemorrhage or perforations due to tumor invasion in adjacent organs (aorta or trachea), or have fistula formation.
  • Hepatic metastasis > 50% of the total liver volume.
  • Received palliative therapy for a local lesion within 2 weeks prior to the first dose.
  • Received systemic treatment with Chinese traditional medicines with anti-cancer indications or immunomodulators (including thymosins, interferons, and interleukins) within 2 weeks prior to the first dose of study treatment.
  • Received systemic within 2 weeks prior to randomization, excluding local use of administered by nasal, inhaled, or other routes, and systemic glucocorticoids at physiological doses (no more than 10 mg/day of prednisone or equivalents), or glucocorticoids to prevent allergies to contrast media.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
746 participants (actual)

Study arms

  • Experimental
    Randomized Part: Experimental: Sintilimab + chemotherapy

    Sintilimab in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil

    Biological: Sintilimab · Drug: Cisplatin · Drug: Paclitaxel · Drug: Fluorouracil

  • Active comparator
    Randomised Part: Active Comparator: Placebo + chemotherapy

    Placebo in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil

    Drug: Cisplatin · Drug: Paclitaxel · Drug: Fluorouracil · Drug: Placebo

  • Experimental
    Open-label part: Sintilimab+ chemotherapy

    Sintilimab in combination with investigator's choice of chemotherapy TP regimen: Cisplatin + paclitaxel or CP regimen: Cisplatin + fluorourcil

    Biological: Sintilimab · Drug: Cisplatin · Drug: Paclitaxel · Drug: Fluorouracil

Interventions

  • BiologicalSintilimab

    For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1

  • 75mg/m\^2 IV Q3W day 1

  • 87.5 mg/m\^2 IV Q3W day 1, day 8 for first cycle and 175mg/m\^2 IV Q3W day 1 after first cycle

  • 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W

  • DrugPlacebo

    For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1

06

What researchers measure

Primary outcomes

  1. OS in overall population

    To compare the overall survival of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

    Time frame: From date of randomization until the date of death from any cause, assessed up to 40 months.

  2. OS in PD-L1 positive population

    To compare the OS of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with PD-L1 positive, unresectable, locally advanced, recurrent or metastatic ESCC

    Time frame: From date of randomization until the date of death from any cause, assessed up to 40 months.

Secondary outcomes

  1. ORR in overall population

    To compare the objective response rate between the two treatment arms in ITT population

    Time frame: From date of randomization up to 28 months.

  2. PFS in overall populationsubjects in ITT population

    To compare the progression-free survival between the two treatment arms in ITT population

    Time frame: From date of randomization up to 28 months

  3. DCR in overall population

    To compare the disease control rate between the two treatment arms in ITT population

    Time frame: From date of randomization up to 28 months

  4. DoR in overall population

    To compare the duration of response between the two treatment arms in ITT population

    Time frame: From date of randomization up to 28 months

  5. ORR - PD-L1 positive

    To compare the objective response rate between the two treatment arms in PD-L1 positive subjects in ITT population

    Time frame: From date of randomization up to 28 months

  6. DCR - PD-L1 positive

    To compare the disease control rate between the two treatment arms in PD-L1 positive subjects in ITT population

    Time frame: From date of randomization up to 28 months

  7. DoR - PD-L1 positive

    To compare the duration of response between the two treatment arms in PD-L1 positive subjects in ITT population

    Time frame: From date of randomization up to 28 months

  8. PFS - PD-L1 positive

    To compare the progression-free survival between the two treatment arms in PD-L1 positive subjects in ITT population

    Time frame: From date of randomization up to 28 months

07

Study locations

48 sites
  • St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center
    Anaheim, California 92835, United States
  • UC Irvine
    Orange, California 92868, United States
  • Rocky Mountain Cancer Centers, LLP
    Denver, Colorado 80218, United States
  • IACT Health - John B. Amos Cancer center
    Columbus, Georgia 31904, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Texas Oncology, P.A.
    Austin, Texas 78705, United States
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington 98684, United States
  • Border Medical Oncology
    East Albury, New South Wales 2640, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Austin Hospital
    Heidelberg, Victoria 3079, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • St John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
  • University Hospital Gent
    Gent, Corneel Heymanslaan 10 9000, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, Herestraat 49 3000, Belgium
  • Cliniques Universitaires Saint-Luc Av.
    Bruxelles, Hippocrate 10 1200, Belgium
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Centre Hospitalier Regional de Verviers
    Verviers, 4800, Belgium
  • Beijing Cancer Hospital
    Beijing, China
  • Hôpital Jean Minjoz
    Bettancourt La Ferree, 25000, France
  • Institut Bergonié
    Bordeaux, 33000, France
  • Centre François Baclesse
    Caen, 14000, France
  • CHU Estaing
    Clermont Ferrand, 63000, France
  • CHU Estaing
    Clermont Ferrand, 63100, France
  • Faculte de Medecine
    Dijon, 21000, France
  • Universite de Bourgogne - Faculte de Medecine - INSERM U866
    Dijon, 21079, France
  • Oscar Lambret Centre
    Lille, 59020, France
  • CHU Hôpital de la Timone
    Marseille, 13005, France
  • Hôpital Européen Georges Pompidou
    Paris, 75015, France
  • CHU de Poitiers
    Poitiers, 86021, France
  • Hôpital Charles-Nicolle de Rouen
    Rouen, 76000, France
  • Institut de Cancérologie de Lorraine
    Vandœuvre-lès-Nancy, 54500, France
  • Országos Onkológiai Intézet
    Budapest, Ráth György U. 7-9 1122, Hungary
  • Jósa András Oktatókórház
    Nyíregyháza, Szent István U. 68 4400, Hungary
  • University Hospital Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital del Mar
    Barcelona, 08001, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario de Fuenlabrada
    Fuenlabrada, 28942, Spain
  • Hospital Universitari de Girona Doctor Josep Trueta
    Girona, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida
    Lleida, 25198, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 280402, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
  • Clínica Universidad de Navarra
    Pamplona, 31008, Spain
  • Parc Taulí Sabadell Hospital Universitari
    Sabadell, 08208, Spain
  • Complexo Hospitalario Universitario de Santiago
    Santiago De Compostela, 15706, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41003, Spain
  • Consorci Hospital General Universitari de València
    Valencia, 46016, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
08

References and documents

Publications

  • Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. PubMed 35440464 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Sep 2021, 32 months.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2018
First posted
Nov 20, 2018
StartActual
Dec 24, 2018
Primary completionActual
Sep 9, 2021
CompletionActual
Jul 29, 2023
Last update
Oct 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03748134
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Dec 24, 2018
Primary completion
Sep 9, 2021
Completion
Jul 29, 2023
Last update
Oct 24, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion